Effectiveness and safety outcomes in patients with EBV plus PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe

被引：0
|
作者：
Trappe, Ralf Ulrich [1 ]
Choquet, Sylvain [2 ]
Clark, Andrew [3 ]
Renard, Cecile [4 ]
Chaganti, Sridhar [5 ]
Comoli, Patrizia [6 ]
Duan, Xinyuan [7 ]
Xing, Baodong [7 ]
Wu, Charley [7 ]
Gamelin, Laurence [7 ]
Terwey, Jan-Henrik [8 ]
Friedetzky, Anke [8 ]
Dierickx, Daan [9 ]
机构：
[1] DIAKO Ev Diakoniekrankenhaus, Bremen, Germany
[2] Hop La Pitie Salpetriere, Paris, France
[3] NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland
[4] Hosp Civils Lyon, Lyon, France
[5] Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England
[6] Fdn IRCCS Policlin San Matteo, Pavia, Italy
[7] Atara Biotherapeut, Thousand Oaks, CA USA
[8] Atara Biotherapeut Switzerland GmbH, Zug, Switzerland
[9] Univ Hosp Leuven, Leuven, Belgium
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
722
引用
收藏
页码：148 / 148
页数：1
相关论文
共 16 条
  • [1] Effectiveness and safety outcomes in patients with EBV+ PTLD treated with allogeneic EBV-specific T-cell immunotherapy (tabelecleucel) under an expanded access program (EAP) in Europe.
    Choquet, Sylvain
    Clark, Andrew
    Renard, Cecile
    Uttenthal, Ben
    Chaganti, Sridhar
    Trappe, Ralf Ulrich
    Comoli, Patrizia
    Duan, Xinyuan
    Xing, Baodong
    Wu, Charley
    Gamelin, Laurence
    Terwey, Jan-Henrik
    Friedetzky, Anke
    Dierickx, Daan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Demographic Criteria and Treatment Outcomes in Patients with EBV plus PTLD treated with Off-the-Shelf EBV-specific CTL (Tabelecleucel) in an Early Access Program ongoing in Europe: Preliminary Analyses
    Choquet, S.
    Uttenthal, B.
    Chaganti, S. R.
    Comoli, P.
    Trappe, R. U.
    Friedetzky, A.
    Xing, B.
    Li, X.
    Polak, T.
    Gamelin, L.
    Terwey, J. -H.
    Dierickx, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 52 - 52
  • [3] Dissecting EBV-specific T-cell responses after allogeneic EBV-specific T-cell transfer for CNS PTLD
    Maecker-Kolhoff, Britta
    Schultze-Florey, Rebecca E.
    Tischer, Sabine
    Kuhlmann, Leonie
    Hundsdoerfer, Patrick
    Koch, Arend
    Ravens, Sarina
    Goudeva, Lilia
    Schultze-Florey, Christian
    Koenecke, Christian
    Blasczyk, Rainer
    Koehl, Ulrike
    Heuft, Hans-Gert
    Prinz, Immo
    Eiz-Vesper, Britta
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 46 - 46
  • [4] Dissecting EBV-specific T-cell responses after successful allogeneic EBV-specific T-cell transfer for CNS PTLD
    Maecker-Kolhoff, Britta
    Schultze-Florey, Rebecca E.
    Tischer, Sabine
    Kuhlmann, Leonie
    Hundsdoerfer, Patrick
    Koch, Arend
    Ravens, Sarina
    Goudeva, Lilia
    Schultze-Florey, Christian
    Koenecke, Christian
    Blasczyk, Rainer
    Koehl, Ulrike
    Heuft, Hans-Gert
    Prinz, Immo
    Eiz-Vesper, Britta
    BONE MARROW TRANSPLANTATION, 2018, 53 : 220 - 221
  • [5] Off-the-shelf EBV-specific T-cell Immunotherapy for EBV-associated PTLD
    O'Reilly, Maeve
    Peggs, Karl S.
    TRANSPLANTATION, 2020, 104 (10) : 1972 - 1973
  • [6] COMPREHENSIVE ACTIVATION PROFILING OF TABELECLEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-SPECIFIC T-CELL IMMUNOTHERAPY
    Ruiz, F.
    Jehng, T.
    Spindler, T.
    Munson, D. J.
    Karlen, J.
    Thota, V.
    Wang, A.
    Chuan, J.
    Yedwabnick, M.
    Dubovksy, J.
    Aftab, B. T.
    CYTOTHERAPY, 2021, 23 (05) : S160 - S160
  • [7] Demographics and treatment outcomes in patients with EBV+ PTLD treated with off-the-shelf EBV-specific CTL under an ongoing expanded access program in Europe: First analyses.
    Choquet, Sylvain
    Chaganti, Sridhar
    Uttenthal, Ben
    Comoli, Patrizia
    Trappe, Ralf Ulrich
    Friedetzky, Anke
    Xing, Baodong
    Li, Xiaoming
    Polak, Tobias Boy
    Gamelin, Laurence
    Terwey, Jan-Henrik
    Dierickx, Daan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Comprehensive Activation Profiling of the Tabelecleucel Library, an Off-the-Shelf, Allogeneic EBV-Specific T-Cell Therapy
    Benoun, Joseph M.
    Ruiz, Fiona J.
    Widmann, Kate
    Jehng, Tiffany
    Spindler, Tassja
    Abraham, Jay
    Minne, Sumer
    Tracy, Karen E.
    Munson, Daniel
    Thota, Vinith
    Wang, Arthur
    Chuan, Johnathan
    Yedwabnick, Matt
    Dubovsky, Jason A.
    BLOOD, 2021, 138
  • [9] TRIAL IN PROGRESS: OBSERVATIONAL, POST-AUTHORISATION SAFETY STUDY TO DESCRIBE SAFETY AND EFFECTIVENESS OF TABELECLEUCEL IN PATIENTS WITH EBV plus PTLD IN A REAL-WORLD SETTING IN EUROPE
    Denjean, Francois
    Zkik, Asmaa
    Battin, Constance
    Blanchet, Sophie
    Carrere, Florence
    Domostoj, Mathias
    Cassan, Valerie
    Randhawa, Pavan
    Valenti, Roberta
    BONE MARROW TRANSPLANTATION, 2024, 59 : 245 - 246
  • [10] Utilizing TCR-Seq to Detect Tabelecleucel, an Allogeneic Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy, Post-Infusion
    Ruiz, Fiona
    Spindler, Tassja J.
    Arthurs, Sumer
    Jehng, Tiffany
    Widmann, Kate
    Benoun, Joseph M.
    Ru, Yuanbin
    Mehta, Aditi
    Dinavahi, Rajani
    Dubovsky, Jason A.
    Nguyen, Cokey
    BLOOD, 2022, 140 : 4966 - 4967
12